AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A composition comprising a nucleic acid of which target is at least one region selected from the group consisting of a juxtamembrane region, a kinase region and an ATP-binding site region in human Flt3 and which can inhibit the function of Flt3, wherein said composition comprises a nucleic acid selected from the group consisting of:

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 3 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 5 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 6 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 8 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 9 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 33 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 34 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 36 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 37 are combined, and

a nucleic acid, wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 39 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 40 are combined.

2-5. (Canceled)

6. **(Currently Amended)** A composition comprising a vector carrying a nucleic acid of which target is at least one region selected from the group consisting of a juxtamembrane region, a kinase region and an ATP-binding site region in human Flt3 and which can inhibit the function of Flt3, wherein said composition comprises a nucleic acid selected from the group consisting of:

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 2 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 3 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 5 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 6 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 8 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 9 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 33 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 34 are combined,

a nucleic acid wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 36 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 37 are combined, and

a nucleic acid, wherein a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 39 and a nucleic acid comprising the nucleotide sequence of SEQ ID NO: 40 are combined.

7-10. (Canceled)

11. (Previously Presented) The composition according to claim 6, wherein the composition comprises a vector having, as a promoter, an RNA polymerase III promoter or an RNA polymerase II promoter.

12. (Original) The composition according to claim 11, wherein the promoter is a promoter selected from the group consisting of a U6 promoter, an H1 promoter, a tRNA promoter and a CMV promoter.

13. (Previously Presented) The composition according to claim 6, wherein the composition comprises, as a basic structure, a vector selected from an adenovirus vector, a lentivirus vector and a retrovirus vector.

14. (Previously Presented) A method of inducing apoptosis, characterized by selectively inhibiting growth of FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells with the composition as defined in claim 1, thereby inducing apoptosis of the FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells.

15. (Original) The method according to claim 14, characterized by using an agent inhibiting kinase in addition to the composition simultaneously or in a manner using one after another, to selectively inhibit growth of FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells, thereby inducing apoptosis of the FLT3 highly expressing cells and/or FLT3/ITD mutation-containing cells.

16. (Previously Presented) A kit for carrying out the method as defined in claim 14, wherein the kit comprises a composition, which contains a nucleic acid of which target is at least one region selected from the group consisting of a juxtamembrane region, a kinase region and an ATP-binding site region in human Flt3 and which can inhibit the function of Flt3.